Analysts expect that Nevro Corp. (NYSE:NVRO – Get Rating) will announce $86.11 million in sales for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Nevro’s earnings. The highest sales estimate is $86.39 million and the lowest is $85.90 million. Nevro posted sales of $88.61 million in the same quarter last year, which suggests a negative year over year growth rate of 2.8%. The company is expected to issue its next earnings results after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Nevro will report full-year sales of $423.00 million for the current fiscal year, with estimates ranging from $421.90 million to $427.18 million. For the next fiscal year, analysts expect that the company will report sales of $482.21 million, with estimates ranging from $470.49 million to $491.33 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Nevro.
Nevro (NYSE:NVRO – Get Rating) last issued its earnings results on Wednesday, February 23rd. The medical equipment provider reported ($0.86) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.86). The business had revenue of $102.80 million during the quarter, compared to analysts’ expectations of $100.70 million. Nevro had a negative net margin of 33.95% and a negative return on equity of 33.06%. The company’s quarterly revenue was down 6.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.21) earnings per share.
Shares of NYSE NVRO opened at $61.69 on Friday. Nevro has a 52 week low of $59.79 and a 52 week high of $182.45. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -16.36 and a beta of 1.03. The firm has a 50-day simple moving average of $70.04 and a 200-day simple moving average of $81.91. The company has a quick ratio of 5.32, a current ratio of 6.46 and a debt-to-equity ratio of 0.50.
In other Nevro news, CEO D Keith Grossman acquired 3,200 shares of the stock in a transaction dated Tuesday, March 8th. The stock was acquired at an average price of $63.59 per share, with a total value of $203,488.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Kashif Rashid acquired 1,500 shares of the stock in a transaction dated Friday, March 11th. The stock was acquired at an average cost of $64.04 per share, with a total value of $96,060.00. The disclosure for this purchase can be found here. Company insiders own 2.60% of the company’s stock.
Large investors have recently modified their holdings of the stock. Parallel Advisors LLC raised its holdings in Nevro by 476.4% in the fourth quarter. Parallel Advisors LLC now owns 317 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 262 shares in the last quarter. Quadrant Capital Group LLC raised its holdings in Nevro by 79.5% in the fourth quarter. Quadrant Capital Group LLC now owns 368 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 163 shares in the last quarter. Signaturefd LLC raised its holdings in Nevro by 7,028.6% in the fourth quarter. Signaturefd LLC now owns 499 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 492 shares in the last quarter. CWM LLC acquired a new stake in Nevro in the fourth quarter valued at approximately $47,000. Finally, FourThought Financial LLC raised its holdings in Nevro by 49.1% in the first quarter. FourThought Financial LLC now owns 683 shares of the medical equipment provider’s stock valued at $49,000 after acquiring an additional 225 shares in the last quarter.
About Nevro (Get Rating)
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems.
- Get a free copy of the StockNews.com research report on Nevro (NVRO)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.